Mechanism of Action: Calcineurin Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Calcineurin Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | 10,813,976 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | 8,614,178 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | 11,413,323 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | 11,154,513 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Harrow Eye | VEVYE | cyclosporine | SOLUTION;OPHTHALMIC | 217469-001 | May 30, 2023 | RX | Yes | Yes | 12,059,449 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | 7,973,081 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
